参考文献/References:
[1]de Meyer T,Nawrot T ,Bekaert S ,et al.Telomere length as cardiovascular?aging?biomarker:JACC review topic of the week[J]. J Am Coll Cardiol,2018,72(7):805-813.
[2]Yeh JK,Wang CY.Telomeres and telomerase in cardiovascular diseases[J]. Genes (Basel),2016,7(9):58.
[3]North BJ,Sinclair DA.The intersection between aging and cardiovascular disease[J]. Circ Res,2012,110(8):1097-1108.
[4]Liu Y, Bloom SI, Donato AJ.The role of senescence,telomere dysfunction and shelterin in vascular aging[J]. Microcirculation,2019,26(2):e12487.
[5]Bhattacharyya J, Mihara K, Bhattacharjee D,et al.Telomere length as a potential biomarker of coronary artery disease [J]. Indian J Med Res,2017,145(6):730-737.
[6]Chi C,Li DJ,Jiang YJ,et al.Vascular smooth muscle cell senescence and age-related diseases:State of the art[J]. Biochim Biophys Acta Mol Basis Dis,2019,1865(7):1810-1821.
[7]Herrmann W, Herrmann M.The importance of telomere shortening for atherosclerosis and mortality[J]. J Cardiovasc Dev Dis,2020,7(3):29.
[8]Vecoli C, Borghini A, Andreassi MG.The molecular biomarkers of vascular aging and atherosclerosis :telomere length and mitochondrial DNA4977 common deletion [J]. Mutat Res Rev Mutat Res,2020,784:108309.
[9]Xu X, Hu H, Lin Y,et al.,Differences in leukocyte telomere length between coronary heart disease and normal population:a multipopulation meta-analysis[J]. Biomed Res Int,2019,2019:5046867.
[10]Opstad TB, Kalstad AA, Pettersen A?,et al.Novel biomolecules of ageing,sex differences and potential underlying mechanisms of telomere shortening in coronary artery disease[J]. Exp Gerontol,2019,119:53-60.
[11]Opstad TB, Kalstad AA, Holte KB,et al.Shorter leukocyte telomere lengths in healthy relatives of patients with coronary heart disease [J]. Rejuvenation Res,2020,23(4):324-332.
[12]Gupta MD, Miglani M, Bansal A,et al.Telomere length in young patients with acute myocardial infarction without conventional risk factors:a pilot study from a South Asian population [J]. Indian Heart J,2020,72(6):619-622.
[13]Ma L, Li Y, Wang J.Telomeres and essential hypertension[J]. Clinical biochemistry,2015,48(16-17):1195-1199.
[14]Tellechea ML, Pirola CJ.The impact of hypertension on leukocyte telomere length:a systematic review and meta-analysis of human studies[J]. J Hum Hypertens,2017,31(2):99-105.
[15]Olivieri F, Mazzanti I, Abbatecola AM,et al.Telomere/telomerase system:a new target of statins pleiotropic effect?[J]. Curr Vasc Pharmacol,2012,10(2):216-224.
[16]Li F, Guo Y, Jiang X,et al.Aspirin inhibits human telomerase activation in unstable carotid plaques[J]. Exp Ther Med,2013,6(1):204-208.
[17]Yetim E, Topcuoglu MA, Yurur Kutlay N,et al.The association between telomere length and ischemic stroke risk and phenotype[J]. Sci Rep,2021,11(1):10967.
[18]Cheng F, Carroll L, Joglekar MV,et al.Diabetes,metabolic disease,and telomere length[J]. Lancet Diabetes Endocrinol,2021,9(2):117-126.
[19]Liu Y, Ma C, Li P,et al.Leukocyte telomere length independently predicts 3-year diabetes risk in a longitudinal study of chinese population[J]. Oxid Med Cell Longev,2020,2020:9256107.
[20]Olivieri F, Lorenzi M, Antonicelli R,et al.Leukocyte telomere shortening in elderly Type2DM patients with previous myocardial infarction[J]. Atherosclerosis,2009,206(2):588-593.
[21]Tamura Y, Takubo K, Aida J,et al.Telomere attrition and diabetes mellitus[J]. Geriatr Gerontol Int,2016,16(suppl 1):66-74.
[22]Sutanto SSI, McLennan SV, Keech AC,et al.Shortening of telomere length by metabolic factors in diabetes:protective effects of fenofibrate[J]. J Cell Commun Signal,2019,13(4):523-530.
[23]Sanchez-Vazquez R, Guío-Carrión A, Zapatero-Gaviria A,et al.Shorter telomere lengths in patients with severe COVID-19 disease[J]. Aging (Albany NY),2021,13(1):1-15.
[24]Yeh JK, Lin MH, Wang CY.Telomeres as therapeutic targets in?heart disease[J]. JACC Basic Transl Sci,2019,4(7):855-865.
相似文献/References:
[1]李乐亮,综述,李萍,等.炎症标志物与颈动脉粥样斑块的稳定性[J].心血管病学进展,2016,(3):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
LI Leliang,LI Ping.Stability of Inflammatory Markers and Carotid Artery Plaque[J].Advances in Cardiovascular Diseases,2016,(12):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
[2]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(12):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[3]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(12):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[4]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(12):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[5]李琦玉 ?张宁 陈婧 黄浙勇.动脉粥样硬化的抗血小板分子靶向治疗[J].心血管病学进展,2019,(5):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
LI Qiyu,ZHANG Ning,CHEN Jing,et al.Anti-Platelet Molecular Targeted Therapy or Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(12):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
[6]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(12):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[7]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(12):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[8]徐侨 刘正霞 鲁翔.白介素22在动脉粥样硬化和2型糖尿病中的作用[J].心血管病学进展,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
XU Qiao,LIU Zhengxia,LU Xiang.IL-22 in Atherosclerosis and Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(12):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
[9]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(12):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
[10]代承忠 彭礼清 余建群 刘静 蒲华霞.双源CT血管成像评价经导管主动脉瓣置入术术前患者颈动脉斑块[J].心血管病学进展,2019,(8):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
DAI Chengzhong,PENG Liqing,YU Jianqun,et al.Evaluation of Carotid Arteries Plaques in Patients Referred for TAVI with Dual-source CT Angiography[J].Advances in Cardiovascular Diseases,2019,(12):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]